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Abstract
Background: Current knowledge of the aetiology of hereditary breast cancer in the four main South African
population groups (black, coloured, Indian and white) is limited. Risk assessments in the black, coloured and Indian
population groups are challenging because of restricted information regarding the underlying genetic contributions
to inherited breast cancer in these populations. We focused this study on premenopausal patients (diagnosed with
breast cancer before the age of 50; n = 78) and triple negative breast cancer (TNBC) patients (n = 30) from the four
South African ethnic groups. The aim of this study was to determine the frequency and spectrum of germline
mutations in BRCA1, BRCA2 and PALB2 and to evaluate the presence of the CHEK2 c.1100delC allele in these
patients.
Methods: In total, 108 South African breast cancer patients underwent mutation screening using a Next-Generation
Sequencing (NGS) approach in combination with Multiplex Ligation-dependent Probe Amplification (MLPA) to
detect large rearrangements in BRCA1 and BRCA2.
Results: In 13 (12 %) patients a deleterious mutation in BRCA1/2 was detected, three of which were novel
mutations in black patients. None of the study participants was found to have an unequivocal pathogenic mutation
in PALB2. Two (white) patients tested positive for the CHEK2 c.1100delC mutation, however, one of these also
carried a deleterious BRCA2 mutation. Additionally, six variants of unknown clinical significance were identified
(4 in BRCA2, 2 in PALB2), all in black patients. Within the group of TNBC patients, a higher mutation frequency was
obtained (23.3 %; 7/30) than in the group of patients diagnosed before the age of 50 (7.7 %; 6/78).
Conclusion: This study highlights the importance of evaluating germline mutations in major breast cancer genes in
all of the South African population groups. This NGS study shows that mutation analysis is warranted in South
African patients with triple negative and/or in premenopausal breast cancer.
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Background
Breast cancer is the most common cancer amongst
South African women with a lifetime risk of 1 in 32 [1].
South Africa is a country consisting of citizens from
diverse ethnic groups. These include: black/African
(79.8 %), white/Caucasian (8.7 %), mixed ancestry/
coloured (9.0 %) and Indian/Asian (2.5 %) (Statistics
South Africa, 2013) [2]. According to the most recent
report from the National Cancer Registry of South Af-
rica, the lifetime risk of developing breast cancer differs
according to ethnicity. The lifetime risk is 1/53 in black
women, 1/15 in white women, 1/21 in coloured women
and 1/20 in Indian women (National Cancer registry,
NHLS, 2006) [1].
Breast cancer has a strong heritable component, with
approximately 15–20 % of cases exhibiting a family his-
tory of the disease [3, 4]. Mutations in genes such as
BRCA1 and BRCA2 lead to autosomal dominant inher-
ited cancer susceptibility and confer a high lifetime risk
of breast cancer, as well as ovarian and other cancers.
Recently it was suggested that the risk to develop breast
cancer for PALB2 mutation carriers is as high as the risk
borne by BRCA2 mutation carriers [5]. Identification of
mutations in these genes through clinical genetic testing
enables patients to undergo screening and prevention
strategies, some of which provide reduced morbidity. In
addition, the c.1100delC mutation in CHEK2 has been
identified as a susceptibility allele with incomplete pene-
trance and is associated with moderate lifetime risks of
breast cancer. Data on the prevalence and spectrum of
mutations in these genes are widely available for individ-
uals of European descent. However, data for cohorts
with African ancestry are scarce [6].
A few South African studies on mutations in BRCA1,
BRCA2 and PALB2 are available [7–10].Three South
African population groups exist in which the presence
of BRCA1/2 founder mutations occur; these are the
Ashkenazi Jewish population [11], the Afrikaans
population [7] and the black Xhosa population [10].
Other family-specific mutations have also been identi-
fied, as is typical of populations elsewhere. Table 1
shows data from studies done in South Africa to date.
These studies have been performed mostly in white
breast cancer patient cohorts. Furthermore, African
populations are known to exhibit greater genomic di-
versity when compared to white populations, and gen-
etic findings in one population cannot necessarily be
extrapolated to another [12]. Consequently, there is a
need to establish the aetiology of inherited breast
cancer in this population. The epidemiology of breast
cancer in South African black populations exhibits a
number of unique trends when compared to other
population groups worldwide. The difference in
underlying genetic architecture, family structure,
limited financial and human resources, limited com-
munity knowledge of breast cancer, limited informa-
tion on family history and historical difficulty
accessing health care, makes it more complex to per-
form risk assessments in these populations [13]. Over-
all, the cancer incidence in sub-Saharan Africa is
lower as compared to developed countries but there
is evidence to suggest changes in the disease burden
as the impact of communicable diseases is mitigated
[14]. South African women tend to be diagnosed with
breast cancer at younger ages [15–17]. However, the
diagnosis only occurs at advanced stage due to the lack of
awareness, access to diagnostic centres available and lim-
ited screening. Hence, the inclusion criterion for a “young”
breast cancer or premenopausal (PM) breast cancer pa-
tient was set at 50 years (See Additional file 1: Table S1).
While this could be due to a younger population struc-
ture, it is possible that these younger women carry unique
mutations in certain genes. Breast cancer in young women
is correlated with aggressive tumour progression, lack of
expression of receptors and poor prognosis [18]. Further-
more, it is often attributed to a genetic predisposition with
germline mutations in the BRCA1/2 genes [19–22]. Youn-
ger women of African descent are known to be in the
high-risk group with decreased survival rates [23].
Another factor that is generally considered as an in-
dicator of genetic susceptibility to breast cancer is the
so-called “triple negative” histological phenotype. Ap-
proximately 15 % of breast cancers lack the expression
of estrogen receptors, progesterone receptors and
HER2/NEU receptors and are known as triple negative
breast cancer (TNBC) [24]. This type of breast cancer
is associated with an aggressive disease progression,
higher histological grade, poor prognosis, high rate of
recurrence and decreased survival rates. The frequent
occurrence of TNBC is strongly correlated with younger
patients of African descent and increased incidence has
been noted among black South African breast cancer
patients [16, 17, 25]. The strong association between
TNBC and mutations in the BRCA1 gene, seen in
European and American populations [26, 27], has not
been investigated in a South African cohort.
This study aimed to evaluate the contribution of germline
BRCA1, BRCA2 and PALB2 mutations and the CHEK2
c.1100delC allele to breast cancer in a high-risk South
African cohort. Individuals included in the study were of
different ethnicities (with a majority from the understudied
black population) and had been diagnosed with premeno-
pausal breast cancer (less than 50 years) or exhibited the
“triple negative” histological phenotype. We chose to ana-
lyse BRCA1, BRCA2 and PALB2 as associated risks are well
established and clinically relevant. In addition, the preva-
lence of CHEK2 c.1100delC was evaluated in this cohort
and compared with the prevalence in individuals of
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European ancestry. We applied a cost efficient next gener-
ation sequencing (NGS) approach for analysis of the
complete coding regions of BRCA1, BRCA2 and PALB2
[28]. Furthermore, large rearrangements have been reported
in both BRCA1 and BRCA2 in several populations which
may be missed by sequencing. We therefore complemented
the sequencing approach with multiplex ligation-dependent
probe amplification (MLPA), for these two genes.
Table 1 Literature overview on BRCA1 and BRCA2 mutations detected in a South African population
Study (Reference) Ethnic group Gene Mutation detected Patients/families tested Frequency (%) Detection method
Yawitch & Van
Rensburg 2000 [51]
Black BRCA1 N/A 0/206 0 PTT and SSCP/HA; limited
to regions with Afrikaner
founder mutations
Reeves et al., 2004 [7] White/Ashkenazi
Jewish
BRCA1 c.68_69delAG 4/18 4.4 PTT and SSCP/HA
White BRCA1 c.329dupA 1/18 1.1
White BRCA1 c.1008dupA 1/18 1.1
White BRCA1 c.1352C > A; p.S451* 1/18 1.1
White/Afrikaner BRCA1 c.1374delC 2/18 2.2
White/Afrikaner BRCA1 c.2641G > T; p.E881* 5/18 5.6
Indian BRCA1 c.4957insC 1/18 1.1
White/Ashkenazi
Jewish







BRCA1 N/A 26/129 20.2 PTT and SSCP/HA and
MLPA
BRCA2 N/A 43/129 33.3
Sluiter et al., 2011 [9] White/Afrikaner BRCA1 + BRCA2 N/A 0/36 MLPA
White/Ashkenazi
Jewish
BRCA1 Ex23-24del 1/30 3.3
BRCA2 N/A 0/30
Van der Merwe et al.,
2012 [10]
Coloured BRCA1 c. 1504_1508delTTAAA 1/105 1.0 PTT and SSCP/HA
BRCA1 c. 2641G > T;p. E881* 1/105 1.0
BRCA2 c. 2826_2829delAATT 1/105 1.0
BRCA2 c. 5771_5774delTTCA 4/105 3.8
BRCA2 c. 6448dupTA 1/105 1.0
BRCA2 c. 7934delG 1/105 1.0





BRCA1 c. 2641G > T; p. E881* 7/302 2.3 SSCP/HA
BRCA1 c. 68_69delAG 2/302 0.7
BRCA1 c. 1374delC 2/302 0.7
BRCA1 c. 5266dupC 1/302 0.3
BRCA2 c. 7934delG 17/302 5.6
BRCA2 c. 5771_5774delTTCA 7/302 2.3
BRCA1 N/A 4/302 1.3 PTT
BRCA2 N/A 5/302 1.7
BRCA1 N/A 2/302 0.7 Sequencing
BRCA2 N/A 2/302 0.7 Sequencing
BRCA1 N/A 18/302 6.0
PTT protein truncation test, SSCP/HA PCR-single strand conformation polymorphism/heteroduplex analysis, N/A mutations were not described; * indicates the presence
of a premature stop codon (cfr. nomenclature HGVS (Human Genome Variation Society))
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Methods
Patients
EDTA blood samples of 108 breast cancer patients were
collected from breast clinics in two state hospitals and a
private hospital in Johannesburg - Charlotte Maxeke
Johannesburg Academic Hospital, Chris Hani Baragwanath
Academic Hospital and Wits Donald Gordon Medical
Centre respectively. Patients were selected if their tumour
was triple-negative (TN), and/or their breast cancer diagno-
sis was premenopausal. All patients were categorized as
black, white, Indian or coloured based on patients’
self-reported data from questionnaires. The cohort
consisted of 85 black patients (78.7 %), 16 white pa-
tients (14.8 %), 5 Indians (4.6 %) and 2 coloureds
(1.9 %). Table 2 presents the overview of the distribu-
tion of ethnicity in the cohort. All patients signed in-
formed consent. Pathology data were obtained from
the hospital files. Genetic counselling was offered to
the patients, prior to obtaining their consent.
The study was approved by the Human Research Ethics
Committee (Medical), University of the Witwatersrand
(No. M091023; M110922; M130450).
DNA extraction
Genomic DNA was extracted from 4 - 6 ml of peripheral
blood using a modified version of the standard salting
out method [29].
Target enrichment, library preparation and sequencing
BRCA1, BRCA2 and PALB2 analysis was successfully
conducted on 108 samples using Illumina’s Miseq desk-
top sequencer. Target enrichment was achieved by high
throughput PCR. Primers were designed for the
complete coding region including splice site regions of
BRCA1 (31 amplicons), BRCA2 (42 amplicons) and
PALB2 (19 amplicons) using Primer XL (www.pxlence.-
com). PCR conditions according to the protocol de-
scribed by De Leeneer et al. were utilised [28].
Library preparation was performed using a modified
version of the Nextera XT (Illumina) protocol. Sequen-
cing was conducted on the MiSeq v2 instrument (Illu-
mina Inc.) according to manufacturer’s instructions. The
approach is described in detail by De Leeneer et al. [28].
Sanger sequencing
All genetic variants and pathogenic mutations identified
via NGS were confirmed with Sanger sequencing. For
confirmation by Sanger sequencing, an independent
PCR amplification step was performed. In addition, the
presence of all deleterious mutations was confirmed on
an independently extracted DNA sample. All fragments
with a coverage of <28× were also analysed by Sanger se-
quencing. For an overview of the number of amplicons
that required Sanger sequencing, refer to Additional file 2:
Table S2.
Nucleotide positions and protein translation correspond
to reference sequence and Genbank account number
NM_007294.3; NP_009225.1 for BRCA1, NM_000059.3;
NP_000050.2 for BRCA2, NM_024675.3; NP_078951.2 for
PALB2 and NM_007194.3 for CHEK2 c.1100delC. Nu-
cleotide numbering uses the A of the ATG translation ini-
tiation start site as nucleotide 1.
MLPA
Large genomic rearrangements and/or gene dosage al-
terations in both the BRCA1 and BRCA2 genes were
screened for in 108 patient samples using MLPA.
BRCA1 MLPA analysis was performed using the SALSA
MLPA P002 probemix (version C2-1113) (MRC-Hol-
land) and BRCA2/CHEK2 MLPA using the SALSA
MLPA P045 probemix (version B3-1113) (MRC-Hol-
land). MLPA setup was performed according to the
manufacturer’s protocol. Fragment detection and sizing
was conducted using capillary gel electrophoresis on the
ABI 3730XL genetic analyser (Applied Biosciences). All
fragments positive for the CHEK2 mutation (c.1100delC)
in the MLPA analysis were confirmed with Sanger
sequencing.
The screening was performed in a research setting.
We used the infrastructure and the protocols supplied
by a molecular diagnostic laboratory with an ISO15189
accreditation.
Data analysis
Mapping of sequencing data was performed with CLC
bio Genomics Workbench v6 software (CLC bio Inc.).
Various in-house scripts were used for sequence analysis
[28]. The Sanger sequencing data were analysed using
SeqPilot v4.1.2 build 512 and SeqSpace v2.5.0. MLPA
data were analysed using Coffalyser (MRC-Holland).
Variants of unknown significance (VUS) were evalu-
ated using in silico mutation interpretation software –
Alamut. We used the computational algorithms of SIFT,
AlignGVGD, Polyphen and Mutation Taster for mis-
sense varaints and the splice site prediction programs
SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer
and Human Splicing Finder for intronic, silent and mis-
sense variants. Based on these predictions and in










Dx < 50 n = 92 TNBC 7 (7.6) 4 (4.3) 2 (2.2) 1 (1.1)
Not TNBC 70 (76.1) 5 (5.4) 2 (2.2) 1 (1.1)
Dx > 50 n = 16 TNBC 8 (50.0) 7 (43.8) 1 (6.3) 0
Total n = 108 85 (78.7) 16 (14.8) 5 (4.6) 2 (1.9)
Dx: Age at diagnosis
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combination with a study of the literature and published
minor allele frequencies, variants were classified in five
classes. Unfortunately, due to limited availability of data,
Bayesian likelihood analyses could not be performed to
calculate the degree of likelihood of pathogenicity.
Therefore, we applied the following rules:
– Variants with a MAF (minor allele frequency) of
> 0.01 were classified as class 1 (data not shown)
– Variants were classified as class 2 if all prediction
programs provided neutral scores (data not shown)
– Variants with two or more programs with
deleterious predictions were allocated to class 3
(Table 5)
– All truncating and unequivocal splice site variants
were considered as deleterious, in addition to
missense variants in the RING domain of BRCA1
(class 4–5) (Table 3)
Statistical analysis
Mutation frequency was calculated with 95 % confidence
intervals. The Fisher’s exact test was used to compare
mutation frequencies in the different groups of patients.
Statistical analysis was performed with Graphpad Prism
software.
Results
In the total study population (n = 108), 15 heterozygous
pathogenic mutations in 14 patients were identified
(12.9 %; 95 % CI = 7.3–20.8 %): six in BRCA1, seven in
BRCA2; two patients were found to carry CHEK2
c.1100delC of which one patient also harboured a dele-
terious BRCA2 mutation. All mutations were identified
by sequencing on Miseq, except a large deletion in
BRCA1 and the CHEK2 c.1100delC mutation which
were detected by MLPA. No unequivocal deleterious
mutations were identified in the PALB2 gene (Table 3).
The distribution of BRCA1/2 mutations among the
different subgroups (TNBC and/or PM) and based on
ethnicity is presented in Table 4. A significantly higher
mutation detection ratio was obtained within the group
of TNBC patients (7/30; 23.3 %; 95 % CI = 9.9–42.3 %)
compared to the premenopausal breast cancer group
without TNBC (6/78; 7.7 %; 95 % CI = 2.9–16.0 %) (p =
0.0432). Not surprisingly, the highest mutation detection
ratio was obtained within the subgroup of TNBC pa-
tients diagnosed before the age of 50 (5/14; 35.7 %; 95 %
CI = 12.7–64.9 %).
The BRCA2 c.7934delG Afrikaner founder mutation
was identified in 2 (white) patients, one with TNBC and
one diagnosed with premenopausal breast cancer. In the
black patient population, two previously unreported mu-
tations were identified in BRCA1 (c.1155G > A and
c.1953_1954insA) and one in BRCA2 (c.582G > A) (see
Table 3). Six (6/85; 7.1 %; 95 % CI = 2.6–14.7 %) patho-
genic BRCA1/2 mutations were observed in the black
population group and five (5/16; 31.3 %; 95 % CI = 11.0–
58.7 %) in the white population group. Two mutations
were identified in the Indian group (2/5; 40 %; 95 % CI
= 5.3–85.3 %) and no mutations were identified either in
Table 3 BRCA1, BRCA2 and CHEK2 germline pathogenic mutations identified in triple negative and premenopausal breast cancer
patients using NGS and MLPA
Patient no. Ethnicity Category Gene Exon Nucleotide change Amino acid change Mutation effect Reference
1 White TNBC/PM BRCA1 4 c.181 T > G p.Cys61Gly Missense [53]
2 Black TNBC/PM BRCA1 4 c.212G > A p.Arg71Lys Missense [54]
3 Indian TNBC/PM BRCA1 10 c.3593 T > A p.Leu1198* Nonsense [55]
4 Black PM BRCA1 10 c.1155G > A p.Trp385* Nonsense Novel
5 Black PM BRCA1 10 c.1953_1954insA p.Lys652fs Frameshift Novel
6 White TNBC BRCA1a 1–2 - - Deletion [30]
7 Black PM BRCA2 7 c.582G > A p.Trp194* Nonsense Novel
8 Black TNBC BRCA2 11 c.5771_5774delTTCA p.Ile1924fs Frameshift [10]
9 White PM BRCA2 11 c.5213_5216delCTTA p.Thr1738fs Frameshift [56]
CHEK2a 11 c.1100delC p.Thr367fs Frameshift [39]
10 White TNBC BRCA2 17 c.7934delG p.Arg2645fs Frameshift [10]
11 White PM BRCA2 17 c.7934delG p.Arg2645fs Frameshift [10]
12 Indian TNBC/PM BRCA2 21 c.8754 + 1G > A Non-coding Splice site [57]
13 Black PM BRCA2 23 c.9097_9098insA p.Thr3033fs Frameshift [53]
14 White PM CHEK2a 11 c.1100delC p.Thr367fs Frameshift [39]
PM Premenopausal
aMLPA results
*indicates the presence of a premature stop codon (cfr. nomenclature HGVS (Human Genome Variation Society))
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BRCA1 or BRCA2 in the two coloured individuals
studied.
To detect large genomic rearrangements in BRCA1
and BRCA2, 108 samples were analysed using MLPA. A
white TNBC patient was found to be heterozygous for a
BRCA1 exon 1a-2 deletion. Several deletions including
these exons but with different breakpoints have previ-
ously been described (for an overview of deletions affect-
ing these exons: [30]). As the number of large
rearrangements reported in PALB2 is extremely small
[31], MLPA for PALB2 was not conducted in this
cohort.
The CHEK2 mutation (c.1100delC) was observed in 2/
108 (1.9 %) patients. Both of these patients were white,
premenopausal patients. One of these patients was also
positive for a deleterious BRCA2 mutation.
In addition to pathogenic mutations, several VUS
were identified: 1 in BRCA1, 3 in BRCA2 and 2 in
PALB2. In Table 5 we provide an overview of the
variants which were classified as class 3 based on in
silico prediction programs. Three of the four in silico
prediction programs used classified the BRCA2 vari-
ant c.9875C > T and c.7712A > G as “probably dam-
aging”. The BRCA2 variant c.9875C > T was
Table 4 BRCA1 and BRCA2 germline pathogenic mutations identified using NGS and MLPA in a South African cohort divided
according to premenopausal diagnosis, triple negative status and ethnicity
Total n = 108 Dx < 50 n = 92 (85.2 %) Dx > 50 n = 16 (14.8 %) Total no.
of mutations per
ethnic group
TNBC n = 14 (13.0 %) Not TNBC n = 78 (72.2 %) TNBC
Black n = 85 (78.7 %) n = 7 n = 70 n = 8 6 (7.1 %)
Mutations BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
c.212G > A - c.1155G > A c.582G > A - c.5771_5774delTTCA
- - c.1953_1954insA c.9097_9098insA - -
White n = 16 (14.8 %) n = 4 n = 5 n = 7 5 (31.3 %)
Mutations BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
c.181 T > G c.7934delG - c.7934delG Exon 1a-2 del -
- - - c.5213_5216delCTTA - -
Indian n = 5 (4.6 %) n = 2 n = 2 n = 1 2 (40.0 %)
Mutations BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
c.3593 T > A c.8754 + 1G > A - - - -
Coloured n = 2
(1.9 %)
n = 1 n = 1 0 0
Mutations - - -
Total mutations per
subgroup
5 (35.7 %) 6 (7.7 %) 2 (12.5 %)
Table 5 In silico predictions obtained for variants of unknown significance in the South African cohort
In silico prediction programs







Black c.1843_1845delTCT BRCA1 p.Ser615del 1 3 - - - - [58–60]
Black c.4798_4800delAAT BRCA2 p.Asn1600del 1 3 - - - - [61]
























aSpectrum of prediction classes (C0, C15, C25, C35, C45, C55, C65) with C0 less likely to be deleterious and C65 most likely
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identified in two black patients. Two of the four pre-
diction programs consulted classified the PALB2 var-
iants c.118A > G and c.2845 T > C as “probably
damaging”.
Discussion
The current study is the first study performing mutation
analyses in BRCA1, BRCA2 and PALB2 and determining
the frequency of CHEK2 c.1100delC in triple negative
and/or premenopausal breast cancer patients in South
Africa through both next generation sequencing and
large rearrangement testing. In total we detected 13
BRCA1/2 mutations in our study cohort of 108 patients
(12 %; 95 % CI = 6.6–19.7 %), thus reinforcing the im-
portant contribution of germline BRCA1 and BRCA2
mutations to inherited breast cancer in this mixed South
Africa cohort. Two patients harboured a CHEK2
c.1100delC mutation, one of them in combination with a
deleterious BRCA2 mutation. Previous studies done on
South African breast cancer populations reported
BRCA1/2 mutation frequenciess of 1 to 25 % [7–10] (for
an overview: see Table 1). The prevalence of mutations
in BRCA1/2 genes in these South African studies varies
by inclusion criteria, ethnicity and mutation screening
techniques used. None of these studies looked specific-
ally at TNBC or premenopausal patients.
The mutation frequency was higher in the subgroup of
TNBC than in the premenopausal breast cancer patients:
23.3 % (7/30) of TNBC patients harbour a pathogenic mu-
tation in either BRCA1 or BRCA2, compared to 12.0 %
(11/92) of all premenopausal breast cancer patients.
Various studies have shown the frequency of BRCA1
mutations to be higher than BRCA2 in patients exhibit-
ing the triple negative phenotype [27, 32, 33]. In our
study 13.3 % (4/30) of TNBC patients had a pathogenic
mutation in BRCA1 compared to 10 % (3/30) in BRCA2.
In our premenopausal cohort, the prevalence of
BRCA1 mutations were similar (5/92; 5.4 %) to BRCA2
mutations (6/92; 6.5 %). BRCA2 mutations are in general
less frequent than BRCA1 in younger white women with
breast cancer [19]. A relatively high number of BRCA2
mutations compared to BRCA1 has been reported in
other studies of young black populations [34–36] and is
contradictory to the scenario in Western populations.
This could be due to the unique genetic background of
African patients.
In the black population, the overall frequency of muta-
tions identified was 7.1 % as compared to 31.3 % in the
white population. Due to the presence of the BRCA2
c.7934delG Afrikaner founder mutation, BRCA2 is the
most important contributor in the white population in
our study cohort, while BRCA1 and BRCA2 mutations
were observed in equal numbers in the black patients
studied. We identified neither the Ashkenazi Jewish nor
the Xhosa mutations in our study groups. Our patient
cohort was recruited in the region of Johannesburg and
is characterized by diverse population structure/ethnic
backgrounds. Therefore we did not anticipate finding a
large number of founder mutations.
The CHEK2 c.1100delC allele contributes to a moder-
ate increased breast cancer risk. The frequency is esti-
mated to be only 1 % in familial breast cancer and 0.5 %
in early onset breast cancer [37, 38]. In the Dutch popu-
lation the prevalence in the general population is 1.1 %,
2.5 % in unselected breast cancer cases, and up to 4.9 %
in familial breast cancer cases [39]. Within our South
African cohort we identified this allele in two white pa-
tients (2/16 = 12.5 %), but in none of the patients from
other ethnicities (0/92). White Afrikaner South Africans
mainly descend from Dutch immigrants which could
explain the higher percentage of CHEK2 c.1100delC in
this cohort.
Previous studies that aimed to clarify the prevalence of
BRCA1/2 mutations in black populations from other
parts of Africa and African Americans have indicated
similar rates [6, 22, 27, 36, 40]; although it is difficult to
compare them since eligibility criteria for study partici-
pation varies extensively. Churpek et al. [40] reported a
pick-up rate of 26 % (47/180) for pathogenic mutations
in a group of black patients with early onset disease (age
of diagnosis <45) and 25 % pick-up rate (26/103) for
pathogenic mutations in triple negative black patients.
Here we report BRCA1/2 mutation frequency of 14 %
(1/7) in the premenopausal triple negative black sub-
group. Our overall mutation detection rate of BRCA1/2
mutations in the black premenopausal breast cancer pa-
tients was 6.5 % (5/77). This is similar to the mutation
rate reported in a study by Pal et al. [22] in young black
African American breast cancer patients (9 %; 13/144).
Although the prevalences are similar among the studies
on West African, African American breast cancers and
our study, we identified 3 novel mutations in the South
African black patients. Furthermore, historical evidence
has shown that African Americans descend from West
African ancestry and so it is not surprising that there
are some differences between these two and the South
African black population, who have some distinct gen-
etic differences at the population level [12, 41].
Large genomic rearrangements in BRCA, detected
with MLPA, were only observed in 0.9 % (1/108) of our
cohort. No large rearrangements were identified in the
black South African breast cancer patients. Generally,
low frequencies for large rearrangements have been re-
ported in black patients, e.g. Pal et al., [22], detected 2
rearrangements in 144 young African-American women
with breast cancer (1.4 %), both of which were in
BRCA1. Zhang et al., [42] reported one BRCA1 exon de-
letion (0.3 %) in a cohort of 352 Nigerian breast cancer
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patients. In another South African study on 52 unrelated
families of European ancestry, only 1 large deletion was
detected in BRCA1 [9]. The lack of detection in BRCA2
led the authors to suggest that large rearrangements in
BRCA2 might not play a role in inherited breast cancer
in South African patients [9]. However, to draw final con-
clusions on the presence of large rearrangements in both
white and black South African breast cancer patients, a
larger patient population should be extensively studied.
Gene sequencing techniques also resulted in the
identification of several VUS. Based on in silico pre-
dictions, we assigned a class (class 1– 3) to each VUS
for clinical interpretation [43]. VUS with a probability
of increased pathogenicity are assigned a higher class.
A number of studies have presented models and per-
formed functional assays for the classification of VUS
in BRCA1/2 [43–46]. We detected six VUS in the 85
black patients of our cohort and none in the 16 white pa-
tients. Also other studies suggested that the frequency of
VUS is higher in patients of African descent, for instance
Nanda et al. [47].
A previous study conducted in a South African cohort
revealed a pathogenic PALB2 mutation in 2 % of early
onset white breast cancer patients [8]. Our cohort con-
sisted of a small number of white patients and no un-
equivocal deleterious mutations in PALB2 were
identified. However two missense variants with suggest-
ive in silico predictions were identified (Table 5) that
warrant further functional analyses. Until recently, the
pathogenic effect of PALB2 missense variants has not
been firmly proven. For some missense variants in the
WD40 domain (from amino acids 853–1186) [48] al-
tered patterns of direct binding to the RAD51C, RAD51
and BRCA2 h proteins in biochemical assays have been
shown [49]. We identified a missense variant in the
WD40 domain (c.2845 T > C; p.Cys949Arg). In order to
elucidate the pathogenicity of missense variants in
PALB2, additional (functional, segregation) analyses are
required.
We focused on identifying mutations in BRCA1,
BRCA2 and PALB2 and the CHEK2 c.1100delC muta-
tion, as the risks for the development of breast and
associated cancers with these genes have been deter-
mined by analysing large study populations. The
search for the remaining genetic contribution towards
breast and ovarian cancer has been carried out exten-
sively, with numerous other genes being identified.
However, at this time, the contribution and associated
risks of mutations in most of these genes is not yet
well established. As the prevalence of mutations in
each of these genes is much lower than germline
BRCA1/2 mutations in the large cohorts (white
American) of patients investigated up until now [50],
international collaborations in populations of different
ethnicities will be required to gain insight into the
exact risks associated with mutations in these genes.
Conclusion
This study is the first to evaluate the use of NGS tech-
nology as a diagnostic testing platform for inherited
breast cancer in a South African cohort. The results pre-
sented herein are particularly relevant for inherited can-
cer testing in the black population of South Africa, a
previously under-researched group. The NGS approach
applied [28] is a cost and time effective approach; it
shows great promise for BRCA1/2 screening in develop-
ing countries like South Africa. The advent of NGS
allows the costs of mutation analysis to fall dramatically,
which should allow testing to become more widely avail-
able, especially in countries with limited healthcare re-
sources, like South Africa. This will create opportunities
to improve patient treatment and challenges for breast
cancer multidisciplinary teams. The finding of a germline
deleterious mutation could alter treatment decisions; for
instance, women with germline mutations might opt for
more radical surgery or may consider prophylactic surgery
to the contralateral breast or ovaries.
Our results have highlighted the contribution of
BRCA1/2 germline mutations in South African breast
cancer patients with triple negative breast tumours and/
or premenopausal breast cancer of different ethnicities.
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